冠心病合并糖尿病患者应用雷帕霉素洗脱支架和紫杉醇涂层支架的疗效观察

Efficacy of Rapamycin Eluting Stent and Paclitaxel Eluting Stent in Patients with Coronary Artery Disease and Diabetes

目的:评价雷帕霉索洗脱支架(Cypher^(TM))和紫杉醇涂层支架(Taxus^(TM))治疗冠心病(CAD)合并2型糖尿病(DM)患者短期疗效和安全性。方法:从2002年12月至2006年3月共116例合并CAD和DM的患者入选本研究,共植入药物涂层支架186个(雷帕霉素洗脱支架97个,紫杉醇涂层支架89个)。观察6个月的主要心血管不良事件(MACE)。结果:接受两种支架植入的患者基本临床特征相似。支架植入成功率100%,95%的患者完成了6个月的随访。雷帕霉素洗脱支架组总的MACE事件发生率约为6．78%(4/59),紫杉醇涂层支架组总的MACE事件发生率约为7．02%(4/57),两组相比无统计学差异。结论:雷帕霉素洗脱支架和紫杉醇涂层支架治疗CAD合并2型DM的患者有相似的疗效。

Objective： To compare the short-term clinical outcomes of rapamycin （sirolimus） eluting stent （CYPHER^TM） and paclitaxel eluting steut （Taxus^TM） in treatment of coronary coronary disease patients with type 2 diabetes. Methods： 116 coronary artery disease and diabetes patients with 186 lesions, were treated with 97 rapamycin eluting stents and 89 paclitaxel eluting stents. 3he short - term（6 months） outcomes were compared between these 2 groups. Results： 3he success rate of steut implantation was 100%, major adverse cardiac eveut（MACE）, during 6 months followup, MACE were 6.78% and 7.02% in the rapamycin eluting stent group and paclitaxel eluting stent group, and there was no significantly difference. Conclusion： The efficacy of rapamycin eluting and paclitaxel eluting stent were similar in coronary heart disease patients with type 2 diabetes.